AptarGroup Inc

AptarGroup makes the pumps, spray valves, caps and other components that dispense, dose and protect medicines and consumer products. It sells them to drug, beauty, food, beverage, personal care and household-goods companies. Those companies build Aptar's parts into their own branded products, from nasal sprays and asthma inhalers to fragrances and food packaging. Aptar has about 5,000 customers, and none accounted for more than 4% of 2025 net sales, which totaled $3.78 billion.

Pharma is the largest segment, with 46% of 2025 sales and 69% of segment profit (adjusted EBITDA). Aptar says it is a leading supplier of nasal spray pumps and metered dose inhaler valves. It also makes rubber-like stoppers, plungers and needle shields for injectable drugs such as vaccines, GLP-1 treatments and biologics. Within Pharma, prescription drugs and digital health made up about 51% of sales, consumer health care 20%, injectables 19% and moisture- and oxygen-absorbing materials 10%.

Beauty brought in 35% of sales but only 18% of segment profit. It sells pumps, airless systems and other dispensers for fragrance, skincare, cosmetics, personal care and home care. Closures, at 19.5% of sales, makes dispensing caps, seals and food service trays. The US accounted for 31.1% of 2025 sales, but Europe as a whole was larger, led by France at 13.6%. Asia added 11.8% and Latin America 7.8%.

• In Q3 FY2026 (ended Sep 30, 2026), revenue was $1.02B, up 6% from a year earlier, and net income was $32.6M (-74.5%).
• For fiscal 2025, revenue was $3.78B (+5.4% year over year; +5.2% a year from FY2020 to FY2025) with a 10.4% net margin.

• Over FY2021–FY2025: $651.5M in buybacks and $536.5M in dividends.
• Regular dividend per share increased 7 years in a row.
• Regular dividends per share grew +4.9% a year over 5 years (FY2020–FY2025).
• Dividends took 30.8% of earnings and 40.3% of free cash flow in the latest fiscal year.
• Shares outstanding changed -3.3% from Feb 14, 2022 to Oct 26, 2026.

Rank among 1514 US companies

Market value at each year end

AptarGroup’s market value went from $4.60B at the end of 2016 to $8.06B on Oct 28, 2026, up 75%; since the end of 2025 it is up 1%.

Form 4 filings from 2025-10-31 to 2026-10-31 (25 read): 0 open-market purchases and 15 sales ($5.2M).

Large shareholders (13G filings)

ETFs with the most weight in ATR

1. Pharma results hinge on customers' drugs. Pharma brought in 46% of 2025 sales and 69% of segment profit (adjusted EBITDA). If customers' drugs lose sales or face approval delays, demand for Aptar's pumps, valves and stoppers falls.
2. Healthcare cost limits could pinch pharma sales. Future government rules to contain healthcare costs could squeeze pharmaceutical customers. That could cut demand for Aptar's drug delivery products, the segment that earns most of its profit.
3. Tariffs raise costs and strain supply. In 2025 the US imposed substantial new tariffs on imports from countries including China, Canada and Mexico, and some countries retaliated. Aptar says this raised costs for certain raw materials and components.
4. Input costs and single-source suppliers. Some materials come from a single supplier or a single plant. A disruption could delay deliveries. If raw material costs rise faster than Aptar can raise prices, profits shrink.
5. Acquisitions could lead to write-downs. Goodwill, the premium paid for past acquisitions, totaled about $1.08 billion at December 31, 2025. If deals such as the Sommaplast purchase underdeliver, write-downs could cut operating income.
6. Currency swings can dent reported results. The US made up 31.1% of 2025 sales, and France alone was 13.6%. When the dollar strengthens, euro and other foreign sales translate into fewer dollars, which can lower reported results.

• Oct 29, 2026 Quarterly results released
• Sep 21, 2026 Investor presentation or announcement
• Sep 10, 2026 Executive or board change
• Jul 30, 2026 Quarterly results released
• May 13, 2026 Executive or board change
• May 7, 2026 Shareholder vote results
• Apr 30, 2026 Quarterly results released
• Mar 17, 2026 Executive or board change
• Feb 5, 2026 Quarterly results released
• Nov 20, 2025 Major agreement signed; Other company announcement

AptarGroup has raised its dividend 7 years in a row. Regular dividends per share rose from $1.44 in 2020 to $1.83 in 2025, about 4.9% a year. Dividends paid in 2025 used 30.8% of earnings and 40.3% of free cash flow (the cash left after capital spending). The yield was 1.13% as of October 28, 2026, so the stock provides little income on its own. Buybacks totaled $651 million from 2021 through 2025, $365 million of it in 2025. The share count fell 3.4% from October 2021 to July 2026.

In the 2008 financial crisis the shares fell 44.4% between June 2008 and March 2009, then took about 18 months from that low to recover. They fell 27% in the 2020 COVID crash and recovered in about 3 months. In the 2022 bear market they fell 23.7% and recovered in about 7 months. The stock also lost 21.4% in 2025. A single stock carries more risk than a diversified fund.